OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press13410.17650/1818-8346-2015-1-16-23HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯCombination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective studyКомбинация бендамустина и ритуксимаба в терапии рецидивирующего и рефрактерного хронического лимфолейкоза: результаты ретроспективного исследованияSemochkinS. V.СёмочкинС. В.
Russian Federation
semochkin_sv@rsmu.ruArshanskayaE. G.АршанскаяЕ. Г.
Russian Federation
ZakharovO. D.ЗахаровО. Д.
Russian Federation
KotelnikovaA. N.КотельниковаА. Н.
Russian Federation
KulikovaS. S.КуликоваС. С.
Russian Federation
OvanesovaE. V.ОванесоваЕ. В.
Russian Federation
KochkarevaYu. B.КочкареваЮ. Б.
Russian Federation
IvanovaV. L.ИвановаВ. Л.
Russian Federation
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, MoscowГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России, Москва1 Ostrovityanova St., Moscow, 117997, Russia Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, MoscowРоссия, 117997, Москва, ул. Островитянова, 1 ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России, Москва1 Samory Mashela St., Moscow, 117198, RussiaРоссия, 117198, Москва, ул. Саморы Машела, 1Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, MoscowФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России, Москва1 Samory Mashela St., Moscow, 117198, Russia S.P. Botkin City Clinical HospitalРоссия, 117198, Москва, ул. Саморы Машела, 1 ГБУЗ «Городская клиническая больница им. С. П. Боткина»5, 2nd Botkinskiy Pr-d., Moscow, 125284, RussiaРоссия, 125284, Москва, 2-й Боткинский пр-д, 5Polyclinic № 11, Affiliate № 4, MoscowГБУЗ «Городская поликлиника № 11, филиал № 4», Москва5 Novatorov St., Moscow, 119421, RussiaРоссия, 119421, Москва, ул. Новаторов, 5Polyclinic № 201, Affiliate № 1, ZelenogradГБУЗ «Городская поликлиника № 201, филиал № 1», ЗеленоградBldg. 225 Zelenograd, 103305, RussiaРоссия, 103305, Зеленоград, корп. 225Polyclinic № 68, MoscowГБУЗ «Городская поликлиника № 68», Москва22, Bldg. 1 Malaya Yakimanka, Moscow, 119180, RussiaРоссия, 119180, Москва, ул. Малая Якиманка, 22, стр. 1S.P. Botkin City Clinical HospitalГБУЗ «Городская клиническая больница им. С. П. Боткина»0406201510116230306201503062015https://oncohematology.abvpress.ru/ongm/article/view/134

Efficacy and safety results of rituximab and bendamustine combination (Scheme BR) in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) are presented. From 01.2012 to 04.2013, the treatment was initiated in 43 patients (21 with relapses are sensitive to the last line of therapy; 22 – with refractory CLL). Median age at start of therapy was 63.5 years (range from 43 to 81 years). In 40 patients response was evaluated according to NCI-WG criteria (1996). Complete remission (CR) is documented in 5 (12.5 %) cases, partial (PR) or nodular partial remission (nPR) in 17 (42.5 %) cases. MRD-negative CR was achieved in 1 (20.0 %) of 5 patients with CR. With 23.5 months of median follow-up for surviving patients 2-year progression-free survival (PFS) was 47.2 ± 8.5 % (median – 18.5 months), overall survival (OS) – 66.9 ± 7.9 % (median not achieved). Hematological toxicity Grade 3–4 occurred in 15 (34.9 %) cases, same degree infectious complicationsin 5 (11.6 %) cases. Patients received 3 or more therapy lines before this treatment (37.5 ± 16.1 % against 74.7 ± 8.3 %; p = 0.016), with «bulky disease» more than 10 cm (0.0 % vs. 75.4 ± 7.5 %; p < 0.001) and received rituximab in combination with chemotherapy in the previous lines, compared to the «naive» cases (44.1 ± 10.5 % against 92.9 ± 6.9 %; p = 0.009) have significantly worsened 2-year OS.

chronic lymphocytic leukemiarelapserefractorybendamustinerituximabхронический лимфолейкозрецидиврефрактерностьбендамустинритуксимаб1. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России, 2014. 250 с. [Malignant neoplasms in Russia in 2012 (morbidity and mortality). Ed.: Kaprin A. D., Starinskiy V. V., Petrova G. V. M.: “P. A. Gertsen MROI”, 2014. 250 pp. (In Russ.)].Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России, 2014. 250 с. [Malignant neoplasms in Russia in 2012 (morbidity and mortality). Ed.: Kaprin A. D., Starinskiy V. V., Petrova G. V. M.: “P. A. Gertsen MROI”, 2014. 250 pp. (In Russ.)].2. Никитин Е. А., Судариков А. Б. Хронический лимфолейкоз высокого риска: история, определение, диагностика и лечение. Клиническая онкогематология 2013;6(1):59–67. [Nikitin E.A., Sudarikov A.B. High-risk chronic lymphocytic leukemia: history, definition, diagnosis, and management. Klinicheskaya Onkogematologiya = Clinical Oncohematology 2013;6(1):59–67. (In Russ.)].Никитин Е. А., Судариков А. Б. Хронический лимфолейкоз высокого риска: история, определение, диагностика и лечение. Клиническая онкогематология 2013;6(1):59–67. [Nikitin E.A., Sudarikov A.B. High-risk chronic lymphocytic leukemia: history, definition, diagnosis, and management. Klinicheskaya Onkogematologiya = Clinical Oncohematology 2013;6(1):59–67. (In Russ.)].3. Dreger P. The evolving role of stem cell transplantation in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2013;27(2):355–69. 4. Hallek M., Fischer K., Fingerle- Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open- label, phase 3 trial. Lancet 2010;376(9747):1164–74.Dreger P. The evolving role of stem cell transplantation in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2013;27(2):355–69. 4. Hallek M., Fischer K., Fingerle- Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open- label, phase 3 trial. Lancet 2010;376(9747):1164–74.5. Eichhorst B., Fink A., Busch R. et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts 2013:526.Eichhorst B., Fink A., Busch R. et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts 2013:526.6. Стругов В. В., Стадник Е. А., Зарицкий А. Ю. Механизм действия и клиническая эффективность нового алкилирующего препарата бендамустин при хроническом лимфолейкозе. Клиническая онкогематология 2011;4(3):217–27. [Strugov V. V., Stadnik E. A., Zaritskiy A. Yu. The mechanism of action and clinical efficacy of new alkylating agents bendamustine in chronic lymphocytic leukemia. Klinicheskaya onkohematologiya = Clinical Oncohematology 2011;4(3):217–27 (In Russ.)].Стругов В. В., Стадник Е. А., Зарицкий А. Ю. Механизм действия и клиническая эффективность нового алкилирующего препарата бендамустин при хроническом лимфолейкозе. Клиническая онкогематология 2011;4(3):217–27. [Strugov V. V., Stadnik E. A., Zaritskiy A. Yu. The mechanism of action and clinical efficacy of new alkylating agents bendamustine in chronic lymphocytic leukemia. Klinicheskaya onkohematologiya = Clinical Oncohematology 2011;4(3):217–27 (In Russ.)].7. Cheson B.D. Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory? Leuk Res 2014;38(11):1267–8.Cheson B.D. Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory? Leuk Res 2014;38(11):1267–8.8. Fischer K., Cramer P., Busch R. et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29(26):3559–66.Fischer K., Cramer P., Busch R. et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29(26):3559–66.9. Cheson B. D., Bennett J. M., Grever M. et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87(12):4990–7.Cheson B. D., Bennett J. M., Grever M. et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87(12):4990–7.10. U. S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published May 28, 2009.U. S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published May 28, 2009.11. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J Amer Statis Assn 1958;53(282):457–81.Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J Amer Statis Assn 1958;53(282):457–81.12. Berty H. P., Shi H., Lyons-Weiler J. Determining the statistical significance of survivorship prediction models. J Eval Clin Pract 2010;16(1):155–65.Berty H. P., Shi H., Lyons-Weiler J. Determining the statistical significance of survivorship prediction models. J Eval Clin Pract 2010;16(1):155–65.13. Загоскина Т. П., Ткаченко С. Б., Голубева М. Е. и др. Сравнительная оценка эффективности флударабинсодержащих режимов и иммунохимиотерапии при хроническом лимфолейкозе.Терапевтический архив 2010;82(1):35–9. [Zagoskina T. P., Tkachenko S. B., Golubeva M. E. et al. Comparative efficacy of fludarabinecontaining regimens and mmunochemotherapy in chronic lymphocytic leukemia. Terapevticheskiy archive = Therapeutic Archives 2010;82 (1):35–9. (In Russ.)].Загоскина Т. П., Ткаченко С. Б., Голубева М. Е. и др. Сравнительная оценка эффективности флударабинсодержащих режимов и иммунохимиотерапии при хроническом лимфолейкозе.Терапевтический архив 2010;82(1):35–9. [Zagoskina T. P., Tkachenko S. B., Golubeva M. E. et al. Comparative efficacy of fludarabinecontaining regimens and mmunochemotherapy in chronic lymphocytic leukemia. Terapevticheskiy archive = Therapeutic Archives 2010;82 (1):35–9. (In Russ.)].14. Aivado M., Schulte K., Henze L. et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002; 29(4 Suppl. 13):19–22.Aivado M., Schulte K., Henze L. et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002; 29(4 Suppl. 13):19–22.15. Niederle N., Megdenberg D., Balleisen L. et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol 2013;92(5):653–60.Niederle N., Megdenberg D., Balleisen L. et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol 2013;92(5):653–60.16. Montillo M., Tedeschi A., Miqueleiz S. et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24(15):2337–42.Montillo M., Tedeschi A., Miqueleiz S. et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24(15):2337–42.17. O, Brien S. M., Kantarjian H. M., Thomas D. A. et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Am Canc Soc 2003;98(12):2657–63.O, Brien S. M., Kantarjian H. M., Thomas D. A. et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Am Canc Soc 2003;98(12):2657–63.18. Hainsworth J. D. Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004:31(1 Suppl. 2):17–21.Hainsworth J. D. Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004:31(1 Suppl. 2):17–21.19. O , Brien S. M., Kay N. E. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9(1):22–31.O , Brien S. M., Kay N. E. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9(1):22–31.20. Spina F., Rezzonico F., Farina L., Corradini P. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. Eur J Haematol 2013;90(4):340–4.Spina F., Rezzonico F., Farina L., Corradini P. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. Eur J Haematol 2013;90(4):340–4.